Correction: Utilizing metformin to prevent metabolic syndrome due to androgen deprivation therapy (ADT): a randomized phase II study of metformin in non-diabetic men initiating ADT for advanced prostate cancer.
Oncotarget（2023）
摘要
In our small study, metformin added to ADT did not show a reduced risk of ADT-related MS or differences in PSA response.
更多查看译文
关键词
metformin,advanced prostate cancer,prostate cancer,metabolic syndrome,non-diabetic
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要